Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
558 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 558 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in… | Phase 1 / Phase 2 | suspended | Jul 24, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Pause for changes in development strategies | Sponsor / business decision |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors… | Phase 1 | terminated | Oct 1, 2018 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Despite demonstrated safety and tolerability the trial was terminated early due to program… | Safety / toxicity |
| NCT02957032 | A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein… | Phase 1 | terminated | Nov 7, 2016 | Philogen S.p.A. | New agents for the same indication impacted on patients' recruitment | Enrollment / accrual |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or… | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | Bellicum Pharmaceuticals | company decision | Sponsor / business decision |
| NCT04166929 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS(Bigeminy) | Phase 2 | terminated | Nov 18, 2019 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | low recruitment | Enrollment / accrual |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With…(BISECT) | Phase 1 | withdrawn | Jul 13, 2022 | Racura Oncology Ltd | commercial reason | Other (stated, no rule matched) |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide…(THRIVE) | Phase 2 / Phase 3 | terminated | Oct 9, 2018 | Bellicum Pharmaceuticals | Funding, portfolio re-prioritization | Funding |
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… | Phase 2 | terminated | Mar 1, 2017 | M.D. Anderson Cancer Center | Study terminated early because of lack of efficacy | Efficacy / futility |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Nov 4, 2020 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | Phase 1 | terminated | Dec 3, 2021 | Biotheryx, Inc. | Business decision | Sponsor / business decision |
| NCT04002115 | Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | Phase 2 | terminated | Jun 28, 2019 | Milton S. Hershey Medical Center | terminated due to low accrual | Enrollment / accrual |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome… | Phase 1 / Phase 2 | terminated | Sep 6, 2019 | H Scott Boswell | Funder requested termination due to halting internal development of TAK-659 | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia… | Early Phase 1 | terminated | Jul 21, 2017 | Amgen | Priortization of other Programs | Other (stated, no rule matched) |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment… | Phase 1 / Phase 2 | withdrawn | Apr 11, 2022 | Children's Oncology Group | Withdrawn per CS0150757 | Other (stated, no rule matched) |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL… | Phase 1 | withdrawn | Aug 29, 2022 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05501171 | Psychological Mobile App for Patients With AML | N/A | terminated | Aug 15, 2022 | Massachusetts General Hospital | the funding agency (blue note therapeutics) pulled out and did not provide funding | Funding |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Phase 1 / Phase 2 | withdrawn | Apr 30, 2019 | Actinium Pharmaceuticals | study postponed | Other (stated, no rule matched) |
| NCT03745352 | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed… | Phase 2 | withdrawn | Nov 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT04679194 | Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After… | Phase 1 | terminated | Dec 22, 2020 | Mana Therapeutics | Product manufacturing | Drug supply |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera… | Phase 1 | withdrawn | May 21, 2021 | Lynk Pharmaceuticals Co., Ltd | sponsor decision | Sponsor / business decision |
| NCT02882321 | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or… | Phase 1 | terminated | Aug 29, 2016 | M.D. Anderson Cancer Center | The study was terminated by the Sponsor for apparent lack of effectiveness. | Other (stated, no rule matched) |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating… | Phase 1 / Phase 2 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | This study was terminated early due to lack of adequate response, and did not move to the Phase II… | Other (stated, no rule matched) |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Oct 14, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT02203773 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo)… | Phase 1 | terminated | Jul 30, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05256277 | NK Cell Therapy for AML | Phase 1 | terminated | Feb 25, 2022 | Zhejiang University | A new study is planed to replace the current study due to IP upgrade | Other (stated, no rule matched) |
| NCT03233074 | Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML…(COSMOS) | — | terminated | Jul 28, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Achievement of scientific objectives | Other (stated, no rule matched) |
| NCT05330377 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | Phase 1 | withdrawn | Apr 15, 2022 | Ayman H Qasrawi | Sponsor withdrew funding | Funding |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected… | Phase 1 | terminated | Mar 14, 2018 | Amgen | Strategic decisions | Sponsor / business decision |
| NCT04067180 | Randomized Clinical Study Assessing Haplo vs. URD in AML | N/A | terminated | Aug 26, 2019 | Karolinska Institutet | Delayed enrollment due to COVID-19 pandemic and other non-alterable world events, including war.… | COVID-19 / pandemic |
| NCT04354025 | Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric… | Phase 2 | withdrawn | Apr 21, 2020 | Washington University School of Medicine | Principal investigator decided not to move forward with the study. | Investigator |
| NCT02863458 | DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies… | — | withdrawn | Aug 11, 2016 | The Cleveland Clinic | Study was a data review, no patient recruitment occurred. | Enrollment / accrual |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | Phase 1 | terminated | Mar 18, 2019 | Weill Medical College of Cornell University | Dose limiting toxicities. | Safety / toxicity |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT04530695 | Diagnosis and Treatment of Periodontal Disease in Patients With AML | N/A | withdrawn | Aug 28, 2020 | Masonic Cancer Center, University of Minnesota | PI left institution and research was cancelled due to his departure | Investigator |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Phase 3 | terminated | Mar 30, 2020 | Goethe University | Change of marketing authorisation holder | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and… | Phase 1 | terminated | Feb 4, 2022 | Magenta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute… | Phase 1 / Phase 2 | terminated | Dec 23, 2014 | Calithera Biosciences, Inc | Business Decision; No Safety or Efficacy Concerns. | Safety / toxicity |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | Phase 1 | terminated | May 27, 2020 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Phase 1 / Phase 2 | terminated | Jul 11, 2017 | GT Biopharma, Inc. | Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE… | Other (stated, no rule matched) |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT03410407 | Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)(AML1617) | — | terminated | Jan 25, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT01570465 | Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients(AML1411) | — | terminated | Apr 4, 2012 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low interest | Other (stated, no rule matched) |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | Phase 1 | terminated | Aug 4, 2020 | Insel Gruppe AG, University Hospital Bern | Insufficient recruitment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 23, 2023source: clinicaltrials